Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
FitzGerald, Thomas J.Bishop-Jodoin, Maryann
Tillman, Gayle
Aronowitz, Jesse N.
Pieters, Richard S.
Balducci, Susan
Meyer, Joshua
Cicchetti, M Giulia.
Kadish, Sidney P.
McCauley, Shelagh
Sawicka, Joanna
Urie, Marcia M.
Lo, Y C.
Mayo, Charles
Ulin, Kenneth
Ding, Linda
Britton, Maureen
Huang, Jiayi
Arous, Edward J.
Document Type
Journal ArticlePublication Date
2008-01-01
Metadata
Show full item recordAbstract
Radiation therapy has been integral to cancer patient care. The skin is an intentional and unintentional target of therapy, and is sensitive to the volume of normal tissue in the radiation therapy treatment field, daily treatment dose (fractionation), and total treatment dose. We must understand the relationship of these factors to patient outcome as we move toward hypofractionation treatment strategies (radiosurgery). Chemotherapy agents and prescription medications may influence therapy-associated sequelae. Understanding this may prevent significant injury and discomfort. This article reviews established platforms of radiation therapy and sequelae associated with skin therapy. Interactions with other agents and possible predisposition to sequelae are reviewed. Skin cancer resulting from treatment and disease processes associated with possible limited outcome are also reviewed.Source
Dermatol Clin. 2008 Jan;26(1):161-72, ix. Link to article on publisher's site
DOI
10.1016/j.det.2007.08.005Permanent Link to this Item
http://hdl.handle.net/20.500.14038/46493PubMed ID
18023776Related Resources
ae974a485f413a2113503eed53cd6c53
10.1016/j.det.2007.08.005